Article
The deubiquitinase inhibitor WP1130 drives nuclear aggregation and reactivation of mutant p53 for selective cancer cell targeting.
The FEBS journal - 1 Jun 2025
Oak Swapnil, Karajgikar Onkar, Gadewal Nikhil, Sulkshane Prasad, Verma Tripti, Gupta Sanjay, Teni Tanuja
Abstract excerpt
Mutations in the TP53 gene may lead to the loss of its tumor suppressor function and the acquisition of oncogenic properties. The enhanced stability of mutant p53 (mutp53) is one of the pivotal factors for its oncogenic functions, rendering proteins implicated in mutp53 stabilization as promising targets for therapeutic intervention. Although deubiquitinases (DUBs) are commonly deregulated in various cancers,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.